MV NIS

Drug Profile

MV NIS

Alternative Names: MV-NIS; Sodium Iodide Simporter Measles Virus

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Vyriad
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Medulloblastoma; Rhabdoid tumour
  • Preclinical Haematological malignancies; Lung cancer

Most Recent Events

  • 02 Nov 2016 The University of California in collaboration with Vyriad plans a phase I trial in Medulloblastoma (Locally recurrent, Second-line therapy or greater, In infants, In children, In adolescents, In adults) (NCT02962167)
  • 01 Nov 2016 Phase-I clinical trials in Medulloblastoma in USA (Intratumoural) (NCT02962167)
  • 01 Nov 2016 Phase-I clinical trials in Rhabdoid tumour in USA (Intratumoural) (NCT02962167)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top